Trial Profile
An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2011
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary)
- Indications Bacterial infections; Rhinosinusitis
- Focus Pharmacokinetics
- 26 Apr 2011 New trial record